ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
26.59
-0.02
(-0.08%)
Cerrado 05 Enero 3:00PM
26.63
0.04
(0.15%)
Fuera de horario: 6:59PM

Discusiones en tiempo real e ideas comerciales: opere con confianza con nuestra poderosa plataforma.

Estadísticas y detalles clave

Último Precio
26.63
Postura de Compra
-
Postura de Venta
-
Volume Operado de la Acción
32,828,049
26.5201 Rango del Día 26.84
24.48 Rango de 52 semanas 31.54
Capitalización de Mercado [m]
Precio Anterior
26.61
Precio de Apertura
26.65
Última hora de negociación
Volumen financiero
US$ 874,746,042
Precio Promedio Ponderado
26.6463
Volumen promedio (3 m)
43,391,566
Acciones en circulación
5,666,990,035
Rendimiento del Dividendo
6.46%
Ratio Precio/Utilidad
71.12
Beneficio por acción (BPA)
0.37
turnover
58.5B
Beneficio neto
2.12B

Acerca de Pfizer Inc

Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 vaccine sales). While it historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers includ... Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 vaccine sales). While it historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor. Mostrar más

Sector
Pharmaceutical Preparations
Industria
Pharmaceutical Preparations
Sitio web
Sede
New York, New York, USA
Fundado
-
Pfizer Inc is listed in the Pharmaceutical Preparations sector of the New York Stock Exchange with ticker PFE. The last closing price for Pfizer was US$26.61. Over the last year, Pfizer shares have traded in a share price range of US$ 24.48 to US$ 31.54.

Pfizer currently has 5,666,990,035 shares in issue. The market capitalisation of Pfizer is US$150.80 billion. Pfizer has a price to earnings ratio (PE ratio) of 71.12.

Flujo de Opciones Pfizer (PFE)

Flujo General

Pesimista

Prima Neta

-60M

Calls / Puts

115.56%

Comp. / Vent.

116.22%

OTM / ITM

10.23%

Sweeps Ratio

1.03%

PFE Últimas noticias

U.S. FDA Approves Pfizer’s BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer

BRAFTOVI in combination with cetuximab and mFOLFOX6 is the first and only combination regimen with targeted therapy approved for use as early as first-line for patients with metastatic...

Pfizer Invites Public to View and Listen to Webcast of February 4 Conference Call with Analysts

Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:30 a.m. EST on Tuesday, February 4, 2025. The...

Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
10.20.75671585319726.4326.8626.243200393926.54704419CS
40.893.4576534576525.7426.8625.064221160026.08220547CS
12-2.73-9.2983651226229.3629.8224.484339156626.63587955CS
26-1.25-4.4835007173627.8831.5424.483689538627.90445888CS
52-3.37-11.23333333333031.5424.483871137127.73036383CS
156-31.78-54.408491696658.4158.5524.483042464336.15787373CS
260-12.12-31.277419354838.7561.7124.483129735237.75065811CS

PFE - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Pfizer?
El precio actual de las acciones de Pfizer es US$ 26.63
¿Cuántas acciones de Pfizer están en circulación?
Pfizer tiene 5,666,990,035 acciones en circulación
¿Cuál es la capitalización de mercado de Pfizer?
La capitalización de mercado de Pfizer es USD 150.8B
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Pfizer?
Pfizer ha negociado en un rango de US$ 24.48 a US$ 31.54 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Pfizer?
El ratio precio/beneficio de Pfizer es 71.12
¿Cuál es el ratio de efectivo a ventas de Pfizer?
El ratio de efectivo a ventas de Pfizer es 2.58
¿Cuál es la moneda de reporte de Pfizer?
Pfizer presenta sus resultados financieros en USD
¿Cuál es el último ingresos anual de Pfizer?
El último ingresos anual de Pfizer es USD 58.5B
¿Cuál es el último beneficio anual de Pfizer?
El último beneficio anual de Pfizer es USD 2.12B
¿Cuál es la dirección registrada de Pfizer?
La dirección registrada de Pfizer es 235 EAST 42ND STREET, NEW YORK, NEW YORK, 10017
¿Cuál es la dirección del sitio web de Pfizer?
La dirección del sitio web de Pfizer es www.pfizer.com
¿En qué sector industrial opera Pfizer?
Pfizer opera en el sector PHARMACEUTICAL PREPARATIONS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
STEMStem Inc
US$ 1.20
(54.74%)
80.16M
KUKEKuke Music Holding Limited
US$ 0.633
(44.55%)
3.92M
BPTBP Prudhoe Bay Royalty Trust
US$ 0.7265
(30.67%)
566.4k
OKLOOklo Inc
US$ 27.22
(24.58%)
23.88M
JOBYJoby Aviation Inc
US$ 9.76
(20.64%)
29.08M
CCMConcord Medical Services Holdings Ltd
US$ 4.50
(-30.23%)
122.16k
ALURAllurion Technologies Inc
US$ 7.675
(-26.41%)
191.08k
RCSPIMCO Strategic Income Fund Inc
US$ 5.74
(-24.17%)
1.93M
PCMPCM Fund Inc
US$ 6.70
(-13.77%)
456.62k
PERFPerfect Corp
US$ 2.56
(-12.33%)
315.91k
STEMStem Inc
US$ 1.20
(54.74%)
80.12M
FFord Motor Company
US$ 9.885
(2.44%)
76.3M
QBTSD Wave Quantum Inc
US$ 9.135
(-4.94%)
63.69M
ACHRArcher Aviation Inc
US$ 11.4825
(19.98%)
54.89M
ABEVAmbev SA
US$ 1.7697
(-3.30%)
51.95M

PFE Discussion

Ver más
Vexari Vexari 4 días hace
Why would that be?
Complete horse hockey..
💨 1 🕳️ 1 🗑️ 1 🚽 1 🤪 1
biotech_researcher biotech_researcher 4 días hace
Complete horse hockey..
👍️ 1 💥 1 💯 1
Vexari Vexari 5 días hace
The bird

Is a metamorphical germ

Eating

Dead cell debris
👎️ 1 🕳️ 1 🗑️ 1 🚽 1 🤪 1
Vexari Vexari 5 días hace
Can not catch something that doesn't exist

Facts don't lie

Open to board discussion
👎️ 1 🗑️ 1 🤥 1 🤪 1 🫵 1
Monroe1 Monroe1 5 días hace
Yep, otherwise they would not be cutting out even some of the most promising collaborations. They are going to have scrap others too in order to stave off bankruptcy possibility in the near future with the pending and growing lawsuits. Other surprises may be waiting too in the form of new and real scrutiny by RFKjr
and the new FDA commissioner. Things are looking ugly and Pfizer is going to pay the consequences for cheating the system, withholding data, and corrupt political collaborations. Not good Pfizer. Looking for investor lawsuits to gain strength.
https://www.businesswire.com/news/home/20241230895593/en/Sangamo-Therapeutics-to-Regain-Full-Rights-to-Hemophilia-A-Gene-Therapy-Program-Following-Pfizer%E2%80%99s-Decision-to-Cease-Development-of-Giroctocogene-Fitelparvovec
👍️0
IHuser IHuser 5 días hace
imo...

Wikipedia • Coronavirus disease 2019 is a contagious disease caused by the coronavirus SARS-CoV-2. The disease spread worldwide, resulting in the COVID-19 pandemic.
The symptoms of COVID-19 can vary but often include fever, fatigue, cough, breathing difficulties, loss of smell, and loss of taste.

Like a snake bit me...... PFE



PFE


(shivering)


IHuser
👍️0
Saving Grace Saving Grace 6 días hace
Yup, this horseshit is being pumped by Wall Street crooks, cooking the books. It's over for big pharma.

Eli Lilly and Company & Pfizer Inc. are a disaster in the making.

👍️0
Vexari Vexari 7 días hace
When financial guidance

Is based on a lie

Where does one go

From there
👎️ 1 🕳️ 1 🗑️ 1 🚽 2 🤪 1
Vexari Vexari 7 días hace
They knew what they were doing

Nothing can stop

What is coming
🎃 1 👎️ 2 💊 1 🗑️ 1 🧻 1
IHuser IHuser 1 semana hace
imo...you are postulating and swaying perception without addressing the science or patents for insured improved health... yea that's because.. I have the market on my side....especially the women now.....and this pos is a done issue stick a fork in it and go play in traffic.....-look at the share price now blue boy ~


PFE





IHuse4
👍️0
IHuser IHuser 1 semana hace
imo...you are very provacative and could wind up bankrupting this entire scam...and should be mindful of the implications...PFE


OK~ go fuck off




PFE



IHuser
👍️0
IHuser IHuser 1 semana hace
imo...Pfizer sponsoring New Years Cornhole tournament in the Hamptons..... get signed up for Viagra CORN Holing into the new year with your billionaire pals.... ...don't say we didn't tell you about a good time and bid flu shots and Polio supplements are door prizes!! , Yaaaaaaay


PFE




IHuser
👍️0
Vexari Vexari 1 semana hace
Gaining strength

Against the cartels grip

Tide is turning

Retribution

Is near
🎃 1 👎️ 1 🕳️ 1 🗑️ 1 🚽 1
Monroe1 Monroe1 1 semana hace
It's all about right and wrong. It is coming down to that. PFE will pay the piper.
👍️0
Vexari Vexari 1 semana hace
The fall of the vaccine agenda

Is the fall of big pharma

The soul of humanity

Is being fought

In health care

Expanding awareness

Is key
👍️ 2 💊 2 🕳️ 1 🗑️ 1 🤪 2 ⤵️ 2
Saving Grace Saving Grace 1 semana hace
Yes, It's over for big Pharma!

👍️0
Saving Grace Saving Grace 1 semana hace
The gloves come off with Big Pharma 2025
👍️0
IHuser IHuser 1 semana hace
imo...yes I am here to pump Pfizer biofunctionality in public restrooms....when my Peter pees and the bunghole is opened we are all about Pfizer watching what's going
On what's why I'm bullish

PFE



IHuser
👍️0
Vexari Vexari 1 semana hace
Genocide must be gentle

So as not to alarm

Those chosen
🎃 1 👍️ 1 💊 1 🕳️ 1 🗑️ 1 🤪 1
MomsSpaghetti MomsSpaghetti 1 semana hace
Pfizer has been exploring new treatments for mood disorders and has a longstanding interest in neurology. It has been over 12 years since their addition of Lyrica for GAD. Their acquisition of MindMed would complement their existing CNS pipeline, particularly for disorders such as anxiety.

Wonder if they would take on that small biotech. Anyone have thoughts?
👍️0
Monroe1 Monroe1 2 semanas hace
https://m3.gab.com/media_attachments/59/1a/1f/591a1f4955dfe351d818c6853909918b.webp?width=568
👍️ 2 👎️ 1 🤪 1
Monroe1 Monroe1 2 semanas hace
The FDA is rushing to Pfizer's aid before the new administration brings out the machete. Notice this news comes out during the Christmas sell off in an effort to slow the massive selling.
So with their COVID "cure" they dumped poison into our bodies that has produced cancers at an alarming new rate for which they are granted alarming new approvals. And this is not the first time either. A little historical DD is appropriate.

I might watch ever so closely for the chance at a quick DEAD CAT BOUNCE and flip.
https://kirschsubstack.com/p/the-cfr-from-the-pfizer-trial-show?publication_id=548354&post_id=153595752&isFreemail=true&r=x7hm&triedRedirect=true
👍️ 1
Monroe1 Monroe1 2 semanas hace
Pfizer #1 worldwide scam of all time. https://kirschsubstack.com/p/the-cfr-from-the-pfizer-trial-show?publication_id=548354&post_id=153595752&isFreemail=true&r=x7hm&triedRedirect=true

Going down, maybe for good....hopefully, and making the world a safer, healthier place.
👍️ 1
IHuser IHuser 2 semanas hace
...imo... colorectoral cancer must be stopped PFE... ...and boogie people off social PFE media... with chapstick lubricant_________






PFE



IHuser
👍️0
Vexari Vexari 2 semanas hace
How long were the trials

Before it was approved U.S. FDA Approves Pfizer’s BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer

https://www.biospace.com/press-releases/u-s-fda-approves-pfizers-braftovi-combination-regimen-as-first-line-treatment-of-braf-v600e-mutant-metastatic-colorectal-cancer
🎃 1 👎️ 1 💊 1 🗑️ 1 🤪 1
axelvento axelvento 2 semanas hace
U.S. FDA Approves Pfizer’s BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer

https://www.biospace.com/press-releases/u-s-fda-approves-pfizers-braftovi-combination-regimen-as-first-line-treatment-of-braf-v600e-mutant-metastatic-colorectal-cancer
👍️ 3 💯 3
Vexari Vexari 2 semanas hace
Some humor

Pharmer's Market Comedy
👎️ 1 🕳️ 1 🗑️ 1 🚽 1
biotech_researcher biotech_researcher 2 semanas hace
You must have bought this in the $40-$50's due to your bottomless bitterness on this board. It will get better..
👍️0
Vexari Vexari 2 semanas hace
Critical thinking

Double message

While proving a point imo...a guy named TRUMP said "some" vaccines are "good" like the Polio one.... uhhhh smh....everybody had Polio in the 16th and 17th and 18th Centuries...~ what a joke. PFE
👇️ 1 🗑️ 1 🤪 1 🧻 1
IHuser IHuser 3 semanas hace
imo...sir with all due respect you have rendered yourself incompetent, abrasive , and inconsequential with respect to this highly contested issue...tyvm

PFE




IHuser
👍️0
IHuser IHuser 3 semanas hace
imo... elect select whoever....I will destroy anything you got...pump bs however...I already told this board...PFE

...I own this issue...PFE...this is my planet and I want it PFE off of my planet....now....thank you.




PFE



IHuser
👍️0
IHuser IHuser 3 semanas hace
imo... practically ZERO % of buyers driving the sp up today were taking long positions...they are merely closing out short positions..for tax considerations....nobody wants any more products from "stogy" Pfizer....believe me~



PFE



IHuser
👍️0
DewDiligence DewDiligence 3 semanas hace
PFE is +4.5% today, which is a big move for such a “stodgy” name. The impetus for the uptick, IMO, is not PFE’s 2025 guidance per se, which was consistent with Street expectations, but rather the comment that the guidance assumes a phase-3 trial for Danuglipron starts during 2025.
👍️ 2 💥 1
DewDiligence DewDiligence 3 semanas hace
PFE issues 2025 financial guidance…

https://s28.q4cdn.com/781576035/files/doc_events/2024/Dec/17/FINAL-PFE-2025-Financial-Guidance-Press-Release.pdf
• Guidance for 2025 sales is $61-64B, up $1.2B from the range of $59.8-62.8B in 2024 guidance after excluding $1.2B of 2024 non-recurring Paxlovid sales to the US federal government stockpile. Thus, on an apples-to-apples basis, 2025 sales growth is expected to be flat to +5%.

• The 2025 sales guidance includes a $1B hit from the Medicare Part- D changes dictated by the IRA, i.e. drugmakers’ mandatory contributions to cover Part-D patients’ deductibles so that each patient’s annual out-of-pocket costs do not exceed $2,000.

• The 2025 sales guidance excludes pro rate equity income from Haleon because PFE is now a <20% shareholder in Haleon.

• Guidance for 2025 non-GAAP EPS is $2.80-3.00, up 10-18% from the 2024 range of $2.45-2.65 after excluding $0.30 of non-recurring 2024 earnings attributable to the Paxlovid item described above.

• 2025 COVID-related revenue is expected to be roughly the same as in 2024, excluding the $1.2B non-recurring Paxlovid item described above.

• 3.25x end-of-2025 target for debt/EBIDTA leverage.

• $500M in efficiency cost reductions to be realized during 2025, which is in addition to the $4.0B in such reductions already achieved during 2024.

CC slides:
https://s28.q4cdn.com/781576035/files/doc_events/2024/Dec/17/FINAL-Full-Year-2025-Guidance-Charts.pdf
👍️ 2
IHuser IHuser 3 semanas hace
imo... it doesn't matter now the bulls have absolutely nothing to say with any integrity whatsoever~PFE

...i own this pos ... me and my battle wounded crew.



PFE




IHuser
👍️0
IHuser IHuser 3 semanas hace
imo... axe, my man seriously, brother you need to really r3lax cuz - man take a little time with the family you know 2hat I'm sayn..s9me you time baby~

PFE


IHuser
👍️0
IHuser IHuser 3 semanas hace
imo....Axel......the whole market knows your heart is not in pumping this nowhere swine sickness gimmick clot stroke scam jab bullshit.....we actually kinda like you and think you deserve a chicken dinner~ PFE

PFE



IHuser
👍️0
IHuser IHuser 3 semanas hace
imo... when my progression-free time runs out on my PFE script~ ...i ~ ../^\____^__/^^\_^\________________________________________________________________________________________________________________________________________________________________________________Flat line_________________




PFE




IHuser
👍️0
axelvento axelvento 3 semanas hace
Ibrance extended median progression-free survival (PFS) by more than 50% in patients with first-line HR+, HER2+ metastatic breast cancer when combined with anti-HER2 and endocrine therapy. The Phase III PATINA trial compared Ibrance to standard of care first-line maintenance therapy after chemotherapy. Median PFS was 44.3 months for the Ibrance group as compared to 29.1 months for those on the standard of care regimen.

https://www.biospace.com/drug-development/pfizers-ibrance-improves-survival-in-new-breast-cancer-indication
🎯 1 👍️ 2 💥 1 ✌️ 1
IHuser IHuser 4 semanas hace
imo...all indigenous tribes were sitting around in tee pees with "POLIO" ....PFE....smh

Total joke....



PFE



IHuser
👍️0
IHuser IHuser 4 semanas hace
imo...a guy named TRUMP said "some" vaccines are "good" like the Polio one.... uhhhh smh....everybody had Polio in the 16th and 17th and 18th Centuries...~ what a joke. PFE


PFE



IHuser
👍️0
Monroe1 Monroe1 4 semanas hace
Someone will trip and the drip will spill becoming a mess. Judge wants that data released! Watch the panic set in.
👍️ 1
Monroe1 Monroe1 4 semanas hace
OMG watch out below. https://dailynewscycle.com/federal-judge-orders-fda-to-release-pfizer-covid-19-trial-documents/
😎 1
Monroe1 Monroe1 4 semanas hace
Each time I look I see more problems heading at Fuzzy Fixer Fyzer and not so modern Mo Durn A.
Who knows, one day soon we may be trading PFE on the OTC.

France Identifies 53 COVID-19 Vaccine Safety Signals
New study reports 190,000 adverse events following COVID-19 vaccination in France, with 25% classified as serious.
Dec. 6
by Nicolas Hulscher, MPH

A new study titled, The enhanced national pharmacovigilance system implemented for COVID-19 vaccines in France: A 2-year experience report, was recently published in the journal Therapies:

One of the major preventative measures developed against coronavirus disease 2019 (COVID-19) was vaccines. To monitor their use and safety of vaccines from the first utilization in humans during clinical development phases to implementation for the general population, an enhanced national pharmacovigilance system was enabled by the French National Agency for Medicines and Health Products Safety in collaboration with the 30 Regional Pharmacovigilance Centres. Here, we review the significant outcomes from a 2-year collaboration experience between the French National Agency for Medicines and Health Products Safety, the 30 Regional Pharmacovigilance Centres, disease-related experts and the pharmacovigilance and risk assessment committee at the European medicine agency. In France, until January 2023, over 155 million doses of COVID-19 vaccines were administrated, and 190,000 adverse events following immunizations (25% classified as serious) were analysed. Altogether 53 potential safety signals were reported to the Pharmacovigilance and Risk Assessment Committee at the European Medicine Agency by the French National Agency for Medicines and Health Products Safety: 13 were confirmed, 24 are still under investigation and 16 were not confirmed.



Below is the comprehensive list of safety signals identified by French pharmacovigilance authorities during their COVID-19 vaccine safety monitoring efforts:
Complete List of 53 COVID-19 Safety Signals in France
Confirmed by EMA (13 Signals)

Myocarditis/pericarditis (mRNA vaccines, Nuvaxovid®)

Heavy menstrual bleeding (mRNA vaccines)

Delayed reactogenicity (mRNA vaccines)

Erythema multiforme (mRNA vaccines)

Guillain-Barré syndrome (Adenovirus-based vaccines)

Facial paralysis (Adenovirus-based vaccines)

Influenza-like illness (Adenovirus-based vaccines)

Thrombosis with thrombocytopenia syndrome (Adenovirus-based vaccines)

Hypersensitivity (Adenovirus-based vaccines)

Capillary leak syndrome (Adenovirus-based vaccines)

Venous thromboembolism (Adenovirus-based vaccines)

Menstrual disorders (non-specific, including heavy menstrual bleeding across vaccine types)

Myocarditis/pericarditis (Recombinant protein-based vaccines)

Under Investigation (24 Signals)

Parsonage-Turner syndrome

Acquired hemophilia

Autoimmune hepatitis

Hearing loss

Vasculitis

Autoimmune hemolytic anemia

Menstrual disorders (excluding heavy menstrual bleeding)

Systemic necrotizing vasculitis

Viral reactivation

Thromboembolic events

Polymyalgia rheumatica

Sarcoidosis

Rheumatoid arthritis

Herpes Zoster

Delayed neurological activation

Cardiovascular secondary adjusters

Myocarditis/pericarditis in special populations

Progressive neuromuscular disease

Vasculitis (general and advanced cases)

Viral reactivation (in autoimmune subgroups)

Autoimmune syndromes with delayed onset

Delayed thrombocytopenia

Post-vaccine fatigue syndrome

Hormonal disruptions (general, excluding heavy menstrual bleeding)

Not Confirmed but Under Surveillance (16 Signals - Inferred based on article, not explicitly mentioned)

Systemic autoimmune responses (general)

Hearing impacts with delayed onset

Cardiovascular irregularities

Hypersensitivity responses with mild symptoms

Neurological subclinical responses

Autoimmune hyperinflammatory conditions

Cyclic immune sensitivity patterns

Long-term joint pain and stiffness

Visual disturbances (mild to moderate)

Delayed rash or cutaneous reactions

Gastrointestinal irregularities

Sleep disturbances linked to vaccine response

Non-specific inflammatory reactions

Menstrual irregularities (non-heavy bleeding)

Musculoskeletal pain syndromes

Dermatological conditions

Even with 53 reported safety signals, this list is most definitely not reflective of all possible adverse events following COVID-19 injection. Moreover, the 25% rate of serious adverse events (totaling 42,500 cases) among reported incidents is deeply concerning. Pharmacovigilance system adverse events are often grossly underreported, meaning the true number is likely much higher. Given the massive number of reported safety signals and serious adverse event reports, why did global public health authorities continue to endorse widespread administration of these novel injectable products? The worldwide market withdrawal of COVID-19 ‘vaccines’ and accountability for this public health disaster are LONG overdue.

Nicolas Hulscher, MPH
👍️ 1
IHuser IHuser 1 mes hace
imo... CEO announcing $4B in cost cutting measures and new company slogan~ PFE

F O O L I N Pfizer




PFE



IHuser
👍️ 1
Vexari Vexari 1 mes hace
The word dripping

Seems more appropriate
Dropping lower. Not looking good here.

Fool me once...

10s coming
👍️ 1 👎️ 1 🕳️ 1 🗑️ 1 😝 1 🚽 1 🤪 1
Lime Time Lime Time 1 mes hace
Dropping lower. Not looking good here.

Fool me once...

10s coming
👍️0
IHuser IHuser 1 mes hace
imo.... when i pop a whole roll of Lyrica Lifesavers into my mouth and roll them around for awhile....uhhhh...my mind turns into a cache of Rock and orchestral music hits with revealing "lyrics" ....and i get swelling upstairs and downstairs~

8=======) - ,, .


PFE




IHuser
👍️0
Monroe1 Monroe1 1 mes hace
Of course they knew, they are the action arm for the deep state they work for. Looking forward to the good guys remaining and the rest of the corrupted get the what they deserve. Remains to be seen. Wonder if they too will all get pardoned!!
😎 1
Monroe1 Monroe1 1 mes hace
https://petermcculloughmd.substack.com/p/breaking-new-study-demands-immediate?publication_id=1119676&post_id=152404520&isFreemail=true&r=x7hm&triedRedirect=true

The tide is rising.
👍️ 1

Su Consulta Reciente

Delayed Upgrade Clock